{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T19:15:23Z","timestamp":1717528523618},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/sj.bdj.2013.628","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T06:00:49Z","timestamp":1373608849000},"page":"17-20","source":"Crossref","is-referenced-by-count":6,"title":["The changing face of oral anticoagulants"],"prefix":"10.1038","volume":"215","author":[{"given":"O. J.","family":"Rider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. B.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,12]]},"reference":[{"key":"BFsjbdj2013628_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/01.CIR.19.1.97","volume":"19","author":"KP Link","year":"1959","unstructured":"Link K P . The discovery of dicumarol and its sequels. Circulation 1959; 19: 97\u2013107.","journal-title":"Circulation"},{"key":"BFsjbdj2013628_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.tpj.6500417","volume":"7","author":"M Wadelius","year":"2007","unstructured":"Wadelius M, Pirmohamed M . Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99\u2013111.","journal-title":"Pharmacogenomics J"},{"key":"BFsjbdj2013628_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2125.2006.02679.x","volume":"61","author":"F Kamali","year":"2006","unstructured":"Kamali F, Pirmohamed M . The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clinical Pharmacol 2006; 61: 746\u2013751.","journal-title":"Br J Clinical Pharmacol"},{"key":"BFsjbdj2013628_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/heartjnl-2012-302101","volume":"98","author":"Y Ahmad","year":"2012","unstructured":"Ahmad Y, Lip G Y . Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012; 98: 1404\u20131406.","journal-title":"Heart"},{"key":"BFsjbdj2013628_CR5","unstructured":"Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. NICE Technology Appraisal 275, 2013."},{"key":"BFsjbdj2013628_CR6","unstructured":"Venous thromboembolism (treatment and long term secondary prevention) rivaroxaban. NICE Technology Appraisal TA261, July 2012."},{"key":"BFsjbdj2013628_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1751-553X.2007.00976.x","volume":"30","author":"PT Onundarson","year":"2008","unstructured":"Onundarson P T, Einarsdottir K A, Gudmundsdottir B R . Warfarin anticoagulation intensity in specialist-based and in computer-assisted dosing practice. Int J Lab Hematol 2008; 30: 382\u2013389.","journal-title":"Int J Lab Hematol"},{"key":"BFsjbdj2013628_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly S J, Ezekowitz M D, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139\u20131151.","journal-title":"N Engl J Med"},{"key":"BFsjbdj2013628_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen M R, Raskob G E, Gallus A, Pineo G, Chen D, Portman R J . Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594\u2013604.","journal-title":"N Engl J Med"},{"key":"BFsjbdj2013628_CR10","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen M R, Ageno W, Borris L C et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776\u20132786.","journal-title":"N Engl J Med"},{"key":"BFsjbdj2013628_CR11","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson B I, Borris L C, Friedman R J et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765\u20132775.","journal-title":"N Engl J Med"},{"key":"BFsjbdj2013628_CR12","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie A G, Lassen M R, Davidson B L et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673\u20131680.","journal-title":"Lancet"},{"key":"BFsjbdj2013628_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar A K, Brenner B, Dahl O E et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31\u201339.","journal-title":"Lancet"},{"key":"BFsjbdj2013628_CR14","unstructured":"Boehringer ingelheim. Pradaxa\u00ae 110mg hard capsules summary of product characteristics."},{"key":"BFsjbdj2013628_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger C B, Alexander J H, McMurray J J et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981\u2013992.","journal-title":"N Engl J Med"},{"key":"BFsjbdj2013628_CR16","unstructured":"Bristol-Myers Squibb-Pfizer Eliquis 2.5 mg film-coated tablets Summary of Product Characteristics."},{"key":"BFsjbdj2013628_CR17","unstructured":"Bayer Xarelto 20 mg film-coated tablets. Summary of product characteristics."},{"key":"BFsjbdj2013628_CR18","unstructured":"Thromboembolic disease. Online information available at \n                    www.medicinescomplete.com\/mc\/bnf\/current\/PHP164thromboembolicdisease.htm\n                    \n                   (subscription required)."},{"key":"BFsjbdj2013628_CR19","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1038\/sj.bdj.2009.112","volume":"206","author":"K Dewan","year":"2009","unstructured":"Dewan K, Bishop K, Muthukrishnan A . Management of patients on warfarin by general dental practitioners in South West Wales: continuing the audit cycle. Br Dent J 2009; 206: E8; discussion 214\u2013215.","journal-title":"Br Dent J"},{"key":"BFsjbdj2013628_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bdj.2007.892","volume":"203","author":"DJ Perry","year":"2007","unstructured":"Perry D J, Noakes T J, Helliwell P S . Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J 2007; 203: 389\u2013393.","journal-title":"Br Dent J"},{"key":"BFsjbdj2013628_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1185\/03007995.2011.654109","volume":"28","author":"A Clemens","year":"2012","unstructured":"Clemens A, Haertter S, Friedman J et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012; 28: 195\u2013201.","journal-title":"Curr Med Res Opin"},{"key":"BFsjbdj2013628_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00228-011-1205-2","volume":"68","author":"A Clemens","year":"2012","unstructured":"Clemens A, van Ryn J, Sennewald R et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol 2012; 68: 607\u2013616.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"BFsjbdj2013628_CR23","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1002\/ajh.23202","volume":"87","author":"S Kaatz","year":"2012","unstructured":"Kaatz S, Kouides P A, Garcia D A et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 Suppl 1: S141\u2013S145.","journal-title":"Am J Hematol"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2013.628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2013.628","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sj.bdj.2013.628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:38:38Z","timestamp":1684622318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/sj.bdj.2013.628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFsjbdj2013628"],"URL":"https:\/\/doi.org\/10.1038\/sj.bdj.2013.628","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}